<DOC>
	<DOCNO>NCT01315210</DOCNO>
	<brief_summary>To evaluate safety determine efficacy D-ribose amelioration fatigue subject fibromyalgia . This phase IIa , randomize , double-blind , placebo-controlled , multi-center , multiple dose study D-ribose versus placebo administer dos 5 g three time day ( TID ) 12-week period subject experience fatigue associate diagnosis fibromyalgia .</brief_summary>
	<brief_title>D-Ribose Fatigue Subjects With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Major must diagnosis primary fibromyalgia , define 1990 American College Rheumatology ( ACR ) Criteria Classification Fibromyalgia make least 6 week prior Pretreatment Screening Visit ; must score ≥5 Subject 's Assessment Fatigue 11point numerical rating scale ( NRS ) Pretreatment Screening Baseline Visits ; take acetaminophen nonopioid analgesic , NSAIDs , fibromyalgia medication , medication induce sleep , prednisone ≤ 10 mg ( equivalent dose glucocorticoid ) , must stable dose ( ) least 4 week prior baseline visit ; must discontinue ribosecontaining product ( include food , drink , supplement ) least 4 week prior Pretreatment Baseline Visit . Major current major depressive episode ( MDE ) ; diagnose autoimmune disease ; diagnose type I type II diabetes ; history cancer , basal cell carcinoma , stage 1 squamous cell carcinoma cervical carcinoma situ , remission least five year prior Pretreatment Screening Visit ; diagnose chronic fatigue syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Fatigue</keyword>
	<keyword>D-Ribose</keyword>
</DOC>